CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)Business Wire • 02/23/23
Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)Business Wire • 02/23/23
Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business Wire • 02/21/23
Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery TechnologiesBusiness Wire • 02/13/23
Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023Business Wire • 01/12/23
Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 ControllerBusiness Wire • 11/14/22
Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022Business Wire • 11/04/22
Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)Business Wire • 11/03/22
Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout NovemberBusiness Wire • 11/01/22
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/22